Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling.

Genome-scale metabolic models (GEMs) have proven useful as scaffolds for the integration of omics data for understanding the genotype-phenotype relationship in a mechanistic manner. Here, we evaluated the presence/absence of proteins encoded by 15,841 genes in 27 hepatocellular carcinoma (HCC) patients using immunohistochemistry. We used this information to reconstruct personalized GEMs for six HCC patients based on the proteomics data, HMR 2.0, and a task-driven model reconstruction algorithm (tINIT). The personalized GEMs were employed to identify anticancer drugs using the concept of antimetabolites; i.e., drugs that are structural analogs to metabolites. The toxicity of each antimetabolite was predicted by assessing the in silico functionality of 83 healthy cell type-specific GEMs, which were also reconstructed with the tINIT algorithm. We predicted 101 antimetabolites that could be effective in preventing tumor growth in all HCC patients, and 46 antimetabolites which were specific to individual patients. Twenty-two of the 101 predicted antimetabolites have already been used in different cancer treatment strategies, while the remaining antimetabolites represent new potential drugs. Finally, one of the identified targets was validated experimentally, and it was confirmed to attenuate growth of the HepG2 cell line.
AuthorsRasmus Agren, Adil Mardinoglu, Anna Asplund, Caroline Kampf, Mathias Uhlen, Jens Nielsen
JournalMolecular systems biology (Mol Syst Biol) Vol. 10 Pg. 721 ( 2014) ISSN: 1744-4292 [Electronic] England
PMID24646661 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Hepatocellular (drug therapy, pathology)
  • Computer Simulation
  • Drug Discovery
  • Genome, Human
  • Humans
  • Liver Neoplasms (drug therapy, pathology)
  • Models, Biological
  • Precision Medicine
  • Proteomics

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: